Table 3.

Treatment regimens of chemotherapy in the studied group

First line chemotherapy
Cisplatin or carboplatin and vinorelbine, n (%)	43 (60.6)
Cisplatin or carboplatin and gemcitabine, n (%)	10 (14.1)
Cisplatin and pemetreksed, n (%)	17 (23.9)
Cisplatin and teoposide, n (%)	1 (1.4)
Second‐line chemotherapy
Cisplatin and vinorelbine, n (%)	1 (1.4)
Cisplatin and gemcitabine, n (%)	2 (2.8)
Carboplatin and paclitaxel, n (%)	1 (1.4)
Carboplatin and docetaxel, n (%)	1 (1.4)
Nivolumab, n (%)	3 (4.2)
Avelumab, n (%)	1 (1.4)
Paclitaxel, n (%)	6 (8.5)
Docetaxel, n (%)	6 (8.5)
Third‐line chemotherapy
Carboplatin and paclitaxel, n (%)	1 (1.4)
Paclitaxel, n (%)	1 (1.4)
Gemcitabine, n (%)	1 (1.4)
Vinorelbine, n (%)	1 (1.4)